CCL2 and colitis: We found that irbesartan suppressed the production of MCP-1, blocked the recruitment of Ly6ChighCCR2+ inflammatory monocytes to the inflamed colon through the MCP-1/CCR2 pathway and inhibited the development of colitis, fibrosis and tumours.